Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Mendelian Randomization Study of PCSK9 and HMG-CoA Reductase Inhibition and Cognitive Function

1 Aug 2022

Abstract excerpt

BACKGROUND: Lipid-lowering therapy with statins and proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibition are effective strategies in reducing cardiovascular disease risk; however, concerns remain about potential long-term adverse neurocognitive effects. OBJECTIVES: This genetics-based study aimed to evaluate the relationships of long-term PCSK9 inhibition and statin use on neurocognitive outcomes....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Alzheimer's disease research and treatments
Share to Dementia and Cognitive Impairment Research
Share to Lipoproteins and Cardiovascular Health

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 35953131
DOI: 10.1016/j.jacc.2022.05.041

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Mendelian Randomization Study of PCSK9 and HMG-CoA Reductase Inhibition and Cognitive FunctionPMID 35953131Read ↗

PCSK9 Inhibitors Do Not Increase Cognitive RiskSemantic proximity Read ↗

<i>PCSK9</i> genetic variants, life-long lowering of LDL-cholesterol and cognition: a large-scale Mendelian randomization studySemantic proximity Read ↗

Comparing the Relationships of Genetically Proxied PCSK9 Inhibition With Mood Disorders, Cognition, and Dementia Between Men and Women: A Drug‐Target Mendelian Randomization StudySemantic proximity Read ↗

Lipid lowering and Alzheimer disease risk: A mendelian randomization study.Semantic proximity Read ↗

PCSK9 Variants, Low-Density Lipoprotein Cholesterol, and Neurocognitive Impairment: Reasons for Geographic and Racial Differences in Stroke Study (REGARDS).Semantic proximity Read ↗

LDL-c Lowering, Ischemic Stroke, and Small Vessel Disease Brain Imaging Biomarkers: A Mendelian Randomization StudySemantic proximity Read ↗

Genetically instrumented LDL-cholesterol lowering and multiple disease outcomes: A Mendelian randomization phenome-wide association study in the UK Biobank.Semantic proximity Read ↗

Causal relationship between PCSK9 inhibitor and common neurodegenerative diseases: A drug target Mendelian randomization study.Semantic proximity Read ↗

Assessing the Impact of PCSK9 and HMGCR Inhibition on Liver Function: Drug-Target Mendelian Randomization Analyses in Four AncestriesSemantic proximity Read ↗

Mendelian randomization of dyslipidemia on cognitive impairment among older AmericansSemantic proximity Read ↗

Risk of Neuropsychiatric Adverse Effects of Lipid-Lowering Drugs: A Mendelian Randomization Study.Semantic proximity Read ↗

Genetically predicted on-statin LDL response is associated with higher intracerebral hemorrhage riskSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.